SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
  • 2
    Lau JWY, Leow CK. Surgical management. In: Leong AS-Y, Liew CT, Lau JWY, Johnson PJ, eds. Hepatocellular Carcinoma: Diagnosis, Investigation and Management. London: Arnold, 1999.
  • 3
    Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-1118.
  • 4
    Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1720-1733.
  • 5
    Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 962-971.
  • 6
    Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324.
  • 7
    Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75: 1401-1407.
  • 8
    Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995; 9: 41-47.
  • 9
    Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992; 52: 6358-6364.
  • 10
    Grady WM, Markowitz SD. TGF-β signaling pathway in tumor suppression. In: Derynck R, Miyazano K, eds. The TGF-β Family. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2008: 889-938.
  • 11
    Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, et al. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg 1999; 177: 209-215.
  • 12
    Sue SR, Chari RS, Kong FM, Mills JJ, Fine RL, Jirtle RL, et al. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995; 222: 171-178.
  • 13
    Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997; 3: 1059-1066.
  • 14
    Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol 2009; 5: 259-271.
  • 15
    Akhurst RJ, Derynck R. TGF-beta signaling in cancer—a double-edged sword. Trends Cell Biol 2001; 11: S44-S51.
  • 16
    Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta 2011; 1815: 214-223.
  • 17
    Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, et al. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 2001; 276: 43604-43610.
  • 18
    Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 2003; 113: 301-314.
  • 19
    Wilkinson DS, Tsai WW, Schumacher MA, Barton MC. Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression. Mol Cell Biol 2008; 28: 1988-1998.
  • 20
    Wilkinson DS, Ogden SK, Stratton SA, Piechan JL, Nguyen TT, Smulian GA, et al. A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene. Mol Cell Biol 2005; 25: 1200-1212.
  • 21
    Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-425.
  • 22
    Chytil A, Magnuson MA, Wright CV, Moses HL. Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis 2002; 32: 73-75.
  • 23
    Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999; 274: 305-315.
  • 24
    Romero-Gallo J, Sozmen EG, Chytil A, Russell WE, Whitehead R, Parks WT, et al. Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene 2005; 24: 3028-3041.
  • 25
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175-1181.
  • 26
    Li MS, Ma QL, Chen Q, Liu XH, Li PF, Du GG, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol 2005; 11: 2564-2569.
  • 27
    Cavin LG, Venkatraman M, Factor VM, Kaur S, Schroeder I, Mercurio F, et al. Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res 2004; 64: 7030-7038.
  • 28
    Belayew A, Tilghman SM. Genetic analysis of alpha-fetoprotein synthesis in mice. Mol Cell Biol 1982; 2: 1427-1435.
  • 29
    Tilghman SM, Belayew A. Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. Proc Natl Acad Sci U S A 1982; 79: 5254-5257.
  • 30
    Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008; 7: 288-295.
  • 31
    Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707-712.
  • 32
    Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006.
  • 33
    Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000; 126: 641-646.
  • 34
    Chen YW, Klimstra DS, Mongeau ME, Tatem JL, Boyartchuk V, Lewis BC. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 2007; 67: 7589-7596.
  • 35
    Nguyen LN, Furuya MH, Wolfraim LA, Nguyen AP, Holdren MS, Campbell JS, et al. Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation. Hepatology 2007; 45: 31-41.
  • 36
    Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002; 23: 435-445.
  • 37
    Hirayama D, Fujimori T, Satonaka K, Nakamura T, Kitazawa S, Horio M, et al. Immunohistochemical study of epidermal growth factor and transforming growth factor-beta in the penetrating type of early gastric cancer. Hum Pathol 1992; 23: 681-685.
  • 38
    Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, et al. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 1992; 16H: 54-61.
  • 39
    Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992; 52: 6949-6952.
  • 40
    Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008; 68: 1809-1819.
  • 41
    Chen H, Egan JO, Chiu JF. Regulation and activities of alpha-fetoprotein. Crit Rev Eukaryot Gene Expr 1997; 7: 11-41.
  • 42
    Song CZ, Siok TE, Gelehrter TD. Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 1998; 273: 29287-29290.
  • 43
    Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995; 23: 3710-3717.
  • 44
    Guo B, Inoki K, Isono M, Mori H, Kanasaki K, Sugimoto T, et al. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Kidney Int 2005; 68: 972-984.
  • 45
    Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010; 51: 523-534.
  • 46
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.